USA flag logo/image

An Official Website of the United States Government

OTHER FUNCTIONS - EFFICACY OF ORAL AMINOGLYCOSIDE-COCHLEATE FORMULATIONS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44AI120021
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
Small Business Information
COORDINATED PROGRAM DEVELOPMENT, LLC
COORDINATED PROGRAM DEVELOPMENT, LLC FLEMINGTON, NJ 08822-4504
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: OTHER FUNCTIONS - EFFICACY OF ORAL AMINOGLYCOSIDE-COCHLEATE FORMULATIONS
Agency: HHS
Contract: N44AI120021
Award Amount: $744,075.00
 

Abstract:

Aminoglycosides are an important class of antibiotics for the treatment of aerobic, gram-negative bacteria (Pseudomonas, Acinetobacter, Enterobacter) and mycobacteria (Mycobacterium tuberculosis, M. avium), causes of serious co-infections in HIV-infected persons. Widespread use of aminoglycosides has been limited due to their toxicity (nephrotoxicity and ototoxicity) and inconvenient route of administration (intravenous or intramuscular); the adverse effects are related to plasma drug levels. For example, use of amikacin for first-line therapy is limited due to poor oral absorption, a short half-life, and serious renal and auditory toxicities which necessitate frequent intravenous administration, with concomitant monitoring of drug levels to ensure that thelevels in plasma remain within a narrow therapeutic window.

Principal Investigator:

Susan Bonitz
908-256-2915
SGBONITZ@GMAIL.COM

Business Contact:

Susan Bonitz
908-256-2915
SGBONITZ@GMAIL.COM
Small Business Information at Submission:

COORDINATED PROGRAM DEVELOPMENT, LLC
COORDINATED PROGRAM DEVELOPMENT, LLC FLEMINGTON, NJ 08822-4504

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No